Teva Pharmaceutical Industries announced strong financial results for the third quarter of 2024, exceeding expectations with a significant rise in profit, driven by robust sales of generics and branded medications. The company raised its financial outlook for 2024, including revenue, adjusted EBITDA, and non-GAAP earnings per share (EPS), projecting a range between $2.40 and $2.50. The announcement follows a pricing of the November 8 weekly straddle at $18.50, indicating a potential move of 9% ahead of the earnings release scheduled for November 6. In a broader context, other companies such as Super Micro Computer, Arm Holdings, Pinterest, DraftKings, and Rivian Automotive also have their quarterly results anticipated, with straddles priced for significant movements in their stock prices as well.